Cynosure develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.

Webcast ImageWebcast
Cynosure Inc. at Canaccord Genuity Medical Technologies & Diagnostics Forum (Replay)
11/20/14 at 11:00 a.m. ET
Cynosure Inc. at Canaccord Genuity Medical Technologies & Diagnostics Forum
Thursday, November 20, 2014 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
CYNO (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$27.70
Change (%) Stock is Up 0.31 (1.13%)
Volume140,900
Data as of 11/26/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

News Releases

November 18, 2014
Cynosure Signs Exclusive Agreement to Market MonaLisa Touch™ in North America for Gynecology Indications
October 28, 2014
Cynosure Reports Record Third-Quarter Revenue of $71.5 Million, Up 18% Year-Over-Year
October 15, 2014
Cynosure To Host Third-Quarter 2014 Financial Results Conference Call On October 28

Upcoming Events

There are currently no events scheduled.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.